Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy

By  

CANCER, Vol. 124, Iss. 3, 2018-02 ,pp. : 587-595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 2, 2018-02 ,pp. : 402-414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparative effectiveness study of patient‐reported outcomes after proton therapy or intensity‐modulated radiotherapy for prostate cancer

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1076-1082

John Wiley & Sons Inc

Access to resources Recommend Favorite

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment

By Lage Maureen J.   Carroll Cathryn A.   Fairman Kathleen A.  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1146-1153

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study

By Choi Seong Hye   Park Kyung Won   Na Duk L.   Han Hyun Jeong   Kim Eun-Joo   Shim Yong S.   Lee Jae-Hong    

Current Medical Research and Opinion, Vol. 27, Iss. 7, 2011-07 ,pp. : 1375-1383

Informa Healthcare

Access to resources Recommend Favorite